Market Cap: $36.23M
AI
Adicet Bio, Inc.
ACET
NASDAQ (NASDAQ Global Market)USD
Market Cap: $36.23M
Johnson & Johnson's Commitment to Advancing Lupus Treatments Johnson & Johnson (NYSE: JNJ) recently reveals topline results from the Phase 2b JASMINE study, which evaluates the efficacy of nipocalimab…
Adicet Bio's Strategic Move: A Reverse Stock Split to Enhance Market Position Adicet Bio, Inc., a clinical-stage biotechnology firm, recently announces a one-for-16 reverse stock split, a strategic ma…
Adicet Bio Implements Reverse Stock Split to Enhance Market Position Adicet Bio, Inc., a clinical-stage biotechnology firm, recently announces a one-for-16 reverse stock split aimed at consolidating i…
Adicet Bio’s Promising Clinical Data for ADI-001 Amid Financial Strategy Concerns Adicet Bio Inc. announces encouraging results from its Phase 1 clinical trial of ADI-001, a therapeutic candidate desi…
Adicet Bio Advances in Autoimmune Treatment Amid Financial Moves Adicet Bio Inc. is currently navigating a pivotal moment as it announces early positive safety and efficacy data from its Phase 1 clini…
Adicet Bio Secures FDA Fast Track Designation for ADI-001 in Lupus Treatment Adicet Bio, Inc., a pioneering biotechnology firm specializing in allogeneic gamma delta T cell therapies, successfully obt…
Adicet Bio Secures Fast Track Designation for Groundbreaking Therapy ADI-001 Adicet Bio, Inc. announces a significant milestone in its development of innovative therapies for autoimmune diseases and c…
Adicet Bio Strengthens Leadership with Strategic Inducement Awards Adicet Bio, Inc., a clinical-stage biotechnology company specializing in allogeneic gamma delta T cell therapies, announces significa…
Adicet Bio Showcases Innovative T Cell Therapies at Upcoming Biotech Conference Adicet Bio, Inc., a clinical-stage biotechnology company based in Redwood City, California, emphasizes its commitment to…
Adicet Bio Strengthens Workforce with New Hire Inducement Award Adicet Bio, Inc. continues to make strategic moves in the biotechnology sector by enhancing its workforce through a recent hiring initia…
Adicet Bio Welcomes New Chief Medical Officer to Propel Clinical Development Adicet Bio, Inc., a clinical-stage biotechnology company specializing in allogeneic gamma delta T cell therapies for cancer…
Adicet Bio Expands Talent Pool with New Inducement Award Adicet Bio, Inc., a clinical-stage biotechnology company specializing in allogeneic gamma delta T cell therapies, announces a significant induc…
Adicet Bio Advances CAR T Cell Therapy for Autoimmune Diseases Adicet Bio, Inc., a clinical-stage biotechnology firm, highlights significant advancements in its ADI-001 Phase 1 GLEAN trial, with clini…
Adicet Bio Advances Clinical Pipeline with Promising CAR T Cell Therapy Adicet Bio, Inc., a clinical-stage biotechnology company, focuses on developing allogeneic gamma delta T cell therapies for chal…
Adicet Bio Advances Allogeneic Gamma Delta T Cell Therapies Amid Investor Engagements Adicet Bio, Inc., a clinical-stage biotechnology firm based in Redwood City, California, focuses on the developmen…
Adicet Bio Strengthens Workforce with New Inducement Awards Adicet Bio, Inc., a clinical-stage biotechnology firm specializing in allogeneic gamma delta T cell therapies for cancer and autoimmune dise…
Adicet Bio Strengthens Workforce with Inducement Awards as Focus on Innovative Therapies Intensifies Adicet Bio, Inc., a clinical-stage biotechnology firm specializing in allogeneic gamma delta T cell…